A day trip thru the medical swamp: sites, acronyms, costs,

New Post Public Reply Private Reply Replies (1) Message Board
WBeacham
489
A day trip thru the medical swamp: sites, acronyms, costs, jargon, options, menus, privatize me!, and other assorted mind-blowing garbage. IOW, anything besides clear, understandable information presented in a way that an average human being might have a chance of deciphering their inflated medical bill. This is what is facing BIEL as they try their level best to obtain the prized CPT code for insurance billing and coverage. And you wonder why they need outside help (consultants) to navigate this quagmire? Stay tuned and read on if you dare. It ain't pretty.

I typed in "CPT I codes" to search using DuckDuckGo search engine. I think BIEL has a better than average chance of getting the CPT I code but who really knows, eh? Will they try only for RRx or try for PEMF in general? Does it make a difference if RRx is prescription only? Does this low vs high frequency play into it? I opened the AMA site, then the CPT option. I know, I should have known better. The following is typical of why the med system is such a fawckin' mess.
Quote:
Medicine’s language—CPT—opens for developers to test innovations - Digital health startups got nearly << $30 billion >> last year, but too often turn out products that burden doctors. AMA effort aims to help change that.

Yea, good luck w/ that. $30 billion for health startups, whatever that means. Go ahead, click on it, see what you get. It's sickening to read. All about helping doctors, like they need it, and practically nothing about providing, you know, actual healthcare to the patient.

Back to the CPT business. The actual wording of requirements for a CPT I are encouraging. The following link gives a decent, understandable rundown of CPT categories I & III. It looks like it is from 2019 so it is 3 yrs old. Items (a) - (f) are the CPT I requirements.

https://medicarepaymentandreimbursement.com/2...s-and.html

a) the service/procedure necessary for the procedure has received approval from the Food and Drug Administration (FDA) for the specific use of devices or drugs;

b) the suggested procedure/service is a distinct service performed by many physicians or other qualified health professionals across the United States;

c) the suggested service/procedure and clinical efficacy of the service/procedure is well established and documented in peer review literature that meets the requirements set in the code change proposal form;

d) the suggested service/procedure is performed with the frequency consistent with the intended clinical use;

e) the suggested service/procedure is neither a fragmentation of an existing procedure/service nor currently reportable by one or more existing codes; and

f) the procedure or service is consistent with current medical practice.

These fit us (BIEL) like a glove. Now you can see why we are so keen to get physicians (and practices) using it in as many places as possible and fund as many studies as we can afford. The more the better to further the idea of a viable alternative to opioids and to establish RRx as a Standard-of-Care.

Here is the official website for CMS.gov. Medicare & Medicaid Services. Wade into the murky depths at your own risk. No lifeguard on duty.

https://medicarepaymentandreimbursement.com/2...s-and.html

Whether or not TENS is covered by insurance is indeterminate for me. I have tried to figure it out and got conflicting answers. If anyone has actual experience w/ this, or anything that sheds light on the whole insurance/CPT mystery, give me shout, please. It may have been at one time covered by CMS but now it seems to be on a case-by-case basis, however that is interpreted. The whole entire medical system was started by quacks and charlatans and continues to this very day. Money and control is first and foremost. Your good health is last, and in many cases, dead last.

I think now would be a good time to look at the competition. https://www.amazon.com/TENs-devices/s?k=TENs+devices - take a look at it, please. Several things can be learned examing all the available stuff. Each one has a controller, wires attached to pads (electrodes), controllers, and tubes of gel. Some of the brand names are: Belifu, Auvon, Neu medics, PUREMED, iReliev, iStim A6, Brilnurse, VPOD, Roscoe, Hollywog, MEDVICE, NURSAL, & MASTOGO. There were at least 6 more pages w/ even more brand names. Some packages included everything, others had bits and pieces for replacement. Controllers have a mash-up of dials, knobs, settings, etc. (on a 'smart' phone or separately) and is anybody's guess what works with what kind of ailment. No, thanks. I like the simplicity of my Actipatch. It works all the time, every time.

I don't know the origins of TENS or who was the first but this tangle of offerings can't be good; or not? Some of these had tens of thousands of 4-5 star ratings. One called 'TENS 7000' (made by Roscoe) had over 72,000 ratings, 79% w/ 5 stars! What to make of this? Is TENS that good? I don't really know as I have never used one. This one claims to have begun in 2008 but does not claim to have FDA clearance. For $29 (reg $37) you get 4 electrode pads, dual channel controller, a battery, 2 lead wires, user manual, and a carrying case. It does not say how long it will last and the legal disclaimer is enough to put anybody off.

TENS will never have what we have - Affordability, Convenience, Effectiveness (A.C.E.). For TENS, how portable is it? Can't use it for more than 60 min at a time w/ no claims to treat or heal the underlying reason for the chronic pain. Forget about wearing it discreetly to work; or while playing sports w/ it on; or wearing it continuously for 30 days, or wear it to bed. Adverse effects include painful vibration and tingling to actual skin burns to shoddy quality.

So, why are people buying all these TENS devices and giving it 5 star reviews? They are desperate to find relief, that's why. Chronic pain has been around for decades. Pills, lotions, gadgets & contraptions, injections are expensive, have limited and temporary effect, don't address the underlying issue, and many have dreadful, long-term side effects. It goes to show you to what lengths sufferers will go to for some relief. With insurance coverage, worldwide distribution network, and a continued awareness campaign (like Twitter currently, which is excellent), Actipatch & RRx will siphon off many TENS users much to the users' relief.

All the things I have mentioned above are addressed by BIEL's Actipatch and RecoveryRx, and all the other products we will offer. No adverse side effects ever reported in over a decade of use; full complete well-documented science in multiple studies easily available at bielcorp.com, more ongoing; well known companies as OEM partners (KT Tape, DonJoy, SAI, PRIM, etc.); available in 38 countries and many online outlets.

Assuming we do obtain a CPT I code (esp'ly RRx) this makes us a prime buyout/merger target; definitely on the auction block and in a very good way. Our value as a company would soar right off the page in a northward direction. I understand completely why the company will not just blurt out info in ref to where we are in the process. There is too much at stake. We still have to submit payment proposals to the insurance companies and negotiate from there. So there is work to be done. Counting chickens ... and all that. Seeing the finish line is no time to slacken the effort and assume victory. The last inch is as important as the first.

It is my belief BIEL will be successful in getting the CPT I code. If big pharma, AMA, FDA, had their way there would be no change at all. The medical establishment, especially in the last 2 yrs, has erased any credibility there might have been left over from the (ongoing) opioid disaster. As far as I'm concerned their collective reputation is in the toilet, where it belongs.

Let me say this in closing (about time!). Bringing in RecoveryRx as an antidote to the opioids would be a win-win-win. For the patients (w1); for us, the investors (w2); for the industry (w3). I'll leave you w/ these parting words -

BUY_MORE_SHARES

later, WBeacham

p.s. - if you are int'd in getting a copy of a prev post (R.I.P.) send me a pm.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Therapy Rules Change: Gameday Ups the Ante

Updated Category News Views 110

Gameday Men's Health: Leading the Safe Peptide Charge Finally, we got some regulatory sanity stepping up to the plate with peptides. You see, the FDA's new interim policy is letting state-licensed compounding pharmacies work their magic with peptides, but only under strict medical watch. And Gameday Men's Health sure ain't wasting any time setting up shop in this fresh...

Continue Reading
Fidelis Care Opens $120K Workforce Grants for Aid

Updated Category News Views 112

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Continue Reading
Chip Earnings Fuel Market Gains Amid Volatility Dip

Updated Category News Views 56

Tech Earnings Drive Market Resilience Amid a climate of economic uncertainty, it's refreshing to see semiconductor and tech earnings offering a little backbone to the market. This week, the S&P 500 climbed 1.51%, while the Nasdaq Composite jumped 1.98% over three sessions. It's like watching Rocky get up off the mat—those indices pushing higher when it seemed like they...

Continue Reading
Read/Write Labs Tackles Brain-Tech Fusion Ambitions

Updated Category News Views 88

Buck up, investors! There's a new player on the field marrying AI and neuroscience with some serious firepower and a respectable roster. Read/Write Labs—what you might've known yesterday as Dandelion Science—has kicked off under a fresh banner, amping up efforts to decode and recode our noggin's electrical orchestra. And with the likes of Jim DiCarlo, Dan Yamins, and...

Continue Reading
Fannie Mae Q3 2026 Earnings Surpass Expectations

Updated Category News Views 84

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Continue Reading
Aktia Bank: Steady Ratings, Focused Expansion in Europe

Updated Category News Views 123

Aktia's Ratings Get a Boost In the world of financial minutiae, it was S&P Global Ratings that took the stage, buzzing about Aktia Bank Plc. The bank just had its ratings held steady with an outlook lift from negative to stable. That's like someone throwing you a life jacket when you're treading water; significant if you're trying to stay afloat, not so much if you've got...

Continue Reading
ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

Updated Category News Views 38

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Continue Reading
VeriSilicon's GLTiny: Game-Changer for Wearable Tech

Updated Category News Views 45

Revolutionizing Wearable Graphics with GLTiny There's a fresh breeze blowing through the world of wearable tech, and VeriSilicon's GLTiny seems to be at the heart of it. When the silicon giant out of Shanghai tossed GLTiny into the mix, it wasn't just throwing another chip on the barbie. Oh no, this is a real pivot towards juicing up those smart gadgets strapped to your...

Continue Reading
Ballard’s HPU Agile-H Poised to Transform Portable Energy

Updated Category News Views 76

Another Step Forward with Hydrogen Ballard's got another ace up its sleeve with the HPU Agile-H. Now here’s the kicker—everyone’s scrambling for cleaner, more portable energy solutions, and Ballard’s stepped up. Born from their acquisition of GeoPura, this lightweight hydrogen powerhouse is engineered for those spots rudely ignored by the grid. Place your bets on...

Continue Reading
Replay Sports Cards Nets STAR Award for Innovation

Updated Category News Views 82

A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Invited to Join Class Action Against Cassava Sciences

Updated Category News Views 133

Important Class Action Notice for Cassava Sciences Investors Investors in Cassava Sciences, Inc. are being urged to take action following the announcement of a class action lawsuit initiated by Pomerantz LLP. This legal action comes as a result of allegations concerning the company’s securities fraud and business practices. Investors who have suffered losses are...

Continue Reading
Altai Resources Streamlines Investment Portfolio for Enhanced Liquidity

Updated Category News Views 155

Altai Resources Repositions Investment Strategy In an exciting move toward strengthening its financial standing, Altai Resources Inc. (TSXV: ATI) has successfully repositioned its investment portfolio. This strategic decision aims to enhance liquidity and effectively manage market risks by transitioning its holdings from marketable securities into cash and cash...

Continue Reading
Joshua Coster Joins Oakworth Capital Bank's Tennessee Board

Updated Category News Views 113

Embracing New Leadership at Oakworth Capital Bank Oakworth Capital Bank is excited to announce a significant addition to its Middle Tennessee Market Board. Joshua Coster, a renowned figure in industrial operations, brings a wealth of experience and innovative thinking to this role. A Wealth of Experience With over twenty years of leadership experience, Coster has excelled...

Continue Reading
Understanding Customer Perception in Quick Service Restaurants

Updated Category News Views 162

Addressing the Perception-Reality Gap in QSRs Every business owner knows the value of customer satisfaction, yet sometimes strong customer sentiment does not equate to viable operational execution. This disparity can pose severe repercussions for brand trust and market share, especially in the fast-moving sector of Quick Service Restaurants (QSRs). The Essence of Customer...

Continue Reading
Cboe Reports Historic Trading Volume Achievements for 2024

Updated Category News Views 221

Cboe Global Markets Achieves Record-Breaking Trading Volume Cboe Global Markets, Inc. (Cboe: NYSE: CBOE) has proudly reported impressive trading volume statistics for the year 2024. As a leading entity in the derivatives and securities exchange market, Cboe continues to demonstrate remarkable growth, clocking unprecedented trading figures across various sectors, including...

Continue Reading